Adelaide Research & Scholarship: Search

Search

Results 31-40 of 40 (Search time: 0.003 seconds).

previous
1
2
3
4
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2012	Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response	White, D.; Hughes, T.
	2011	Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells	Tang, M.; Gonen, M.; Quintas-Cardama, A.; Cortes, J.; Kantarjian, H.; Field, C.; Hughes, T.; Branford, S.; Michor, F.
	2007	Imatinib increases the intracellular concentration of nilotinib which may explain the observed synergy between these drugs	White, D.; Saunders, V.; Quinn, S.; Manley, P.; Hughes, T.
	2003	Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis	Branford, S.; Rudzki, Z.; Walsh, S.; Parkinson, I.; Grigg, A.; Szer, J.; Taylor, K.; Hermann, R.; Seymour, J.; Arthur, C.; Joske, D.; Lynch, K.; Hughes, T.
	2011	BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib teatment	Stein, A.; Bottino, D.; Modur, V.; Branford, S.; Kaeda, J.; Goldman, J.; Hughes, T.; Radich, J.; Hochhaus, A.
	2008	Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications	Hiwase, D.; Saunders, V.; Hewett, D.; Frede, A.; Zrim, S.; Dang, P.; Eadie, L.; To, L.; Vaz de Melo, J.; Kumar, S.; Hughes, T.; White, D.
	2012	Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia	Yeung, D.; Hughes, T.
	2008	Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: Implications for defining sensitivity in minimal residual disease	Ross, D.; Watkins, D.; Hughes, T.; Branford, S.
	2013	Dasatinib targets chronic myeloid leukemia-CD34⁺ progenitors as effectively as it targets mature cells	Hiwase, D.; Saunders, V.; Nievergall, E.; Ross, D.; White, D.; Hughes, T.
	2017	Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells	Wang, J.; Lu, L.; Kok, C.; Saunders, V.; Goyne, J.; Dang, P.; Leclercq, T.; Hughes, T.; White, D.